Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies

Table 2

Incidence of nonphospholipidosis histological findings (HFs) for liver, kidney, lung, adrenals, and lymphoid tissues for 46 phospholipogenics and 62 nonphospholpogenics. Results are presented as the total number of compounds exhibiting (or not exhibiting—“No findings”) the given histological finding and the percentage of the total number of compounds in that category. ChiSquare values of ≥3.84 conferred statistical significance at 𝑃<0.05*. Statistical significance was achieved for select histological findings in liver, lung, thymus, lymph node, and spleen but not kidney and adrenal glands. HF: histological findings.

	Phospholipogenics		Nonphospholipogenics		Chi-Sq*
	Total number	Percent of total compounds	Total number	Percent of total compounds
Liver
Necrosis/degeneration	22	48	13	21	8.7*
Hypertrophy	12	26	11	18	1.1
Reduced glycogen vacuolation	8	17	5	8	2.2
No findings	14	30	32	52	4.8*
Kidney
Necrosis/degeneration	8	17	6	10	1.4
Nephropathy	5	11	5	8	0.25
No findings	27	59	40	65	0.28
Lung
Pneumonitis	5	11	0	0	7.1*
Oedema	3	7	1	2	1.8
Alveolitis	3	7	0	0	4.2*
No findings	34	74	61	98	14.9*
Adrenal gland
Hypertophy	5	11	5	8	0.25
Necrosis	4	9	2	3	1.5
No findings	30	65	46	74	1.1
Thymus
Lymphocytolysis, lymphoid depletion	16	35	6	10	10.3*
Atrophy/involution	13	28	16	26	0.08
No findings	22	48	43	69	5.1
Lymph node
Lymphocytolysis, lymphoid depletion	12	26	1	2	14.9*
Atrophy	2	4	5	8	0.6
No findings	28	61	52	84	7.3*
Spleen
Lymphocytolysis, lymphoid depletion	8	17	0	0	11.7*
Altered hematopoiesis	4	9	6	10	0.01
Atrophy	4	9	3	5	0.65
Apoptosis	3	7	0	0	4.2*
No findings	30	65	52	84	5.0*